Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3623713 | 0.90 | HSD11B1 (0.54) | HSD11B1ALDH1A1 | |
| SCHEMBL3621843 | 0.83 | NPSR1 (0.48) | HSD11B1 | |
| SCHEMBL3620712 | 0.80 | HSD11B1 (0.64) | HSD11B1ALDH1A1 | |
| SCHEMBL3620959 | 0.79 | HSD11B1 (0.80) | HSD11B1POLBLMNAATMHDAC1 | |
| SCHEMBL3621587 | 0.78 | HSD11B1 (0.61) | HSD11B1 | |
| SCHEMBL3618287 | 0.77 | HSD11B1 (1.00) | HSD11B1ALDH1A1 | |
| SCHEMBL3618676 | 0.77 | HSD11B1 (0.59) | HSD11B1 | |
| SCHEMBL3623669 | 0.69 | HSD11B1 (0.84) | HSD11B1LMNAHDAC1ALDH1A1 | |
| SCHEMBL3621424 | 0.68 | HSD11B1 (1.00) | HSD11B1LMNAHDAC1ALDH1A1 | |
| SCHEMBL3620390 | 0.67 | HSD11B1 (1.00) | HSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094263-B1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-16 | — | — | EP | claimed |
| EP-2318368-B1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-16 | — | — | EP | claimed |
| US-8183265-B2 | 2-adamantyl-butyramide derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2012-05-22 | — | — | US | claimed |
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | claimed |
| EP-2094263-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2009-09-02 | — | — | EP | claimed |
| WO-2008074384-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11βETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2008-06-26 | — | — | WO | claimed |
| EP-1935420-A1 | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors | Merck Sante (FR) | 2008-06-25 | — | — | EP | claimed |
| EP-2094263-B1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-8183265-B2 | 2-adamantyl-butyramide derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20110286969-A1 | DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SCHERING CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| EP-2094263-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074384-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11βETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2008-06-26 | — | — | WO | disclosed |
| EP-1935420-A1 | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors | Merck Sante (FR) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | HSD11B1, HSD11B2, CYP11B1 | HSD11B1 1/4885POLB 1897/4885LMNA 3179/4885 |
| US-20110286969-A1 | DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | PEPD, PREP, ACE | HSD11B1 153/4885POLB 1856/4885LMNA 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.